PARSIPPANY, N.J., Oct. 18, 2011 /PRNewswire/ -- Pacira Pharmaceuticals, Inc. (Nasdaq: PCRX) today announced that new data discussing the pharmacoeconomic impact of EXPAREL™ (bupivacaine liposome extended-release injectable suspension), the company's lead investigational product for postsurgical pain management, will be presented during a podium presentation at the American College of Surgeons (ACS) 97th Annual Clinical Congress in San Francisco on Wednesday, October 26. Another podium presentation highlighting the pain control properties and related impact on opioid use of EXPAREL compared to bupivacaine HCl across three surgical models will be presented on Monday, October 24.
Currently under review with the U.S. Food and Drug Administration, EXPAREL is an innovative, long-acting bupivacaine that has been evaluated in multiple Phase 2 and Phase 3 clinical studies to assess prolonged postsurgical analgesia for up to 72 hours with a single-dose local administration into the surgical site. The drug combines bupivacaine with DepoFoam®, Pacira's proven product delivery technology that delivers medication over a desired time period.
The schedule for Pacira podium presentations are as follows:
Presentation Title: Comparison of Immediate-Release Bupivacaine vs. EXPAREL™ (Bupivacaine Extended-Release Liposome Injection) on Opioid Requirements and Related Adverse Events from Phase 2 and 3 Studies Utilizing Multimodal Analgesia Across Multiple Surgical Models
Presented by: Sonia Ramamoorthy, M.D., associate professor of surgery at the University of California, San Diego
Date & Time: Monday, October 24 from 9:45-11:15 a.m. PDT
Location: Moscone Convention Center, Moscone West, 3rd Floor, Room 3014/3016/3018
Presentation Title: EXPAREL™ (Bupivacaine
|SOURCE Pacira Pharmaceuticals, Inc.|
Copyright©2010 PR Newswire.
All rights reserved